GLP-1 Medications and Exercise Participation

Member Exclusive Content

Sign up to be a member to access this content.

Join now!

Already a member? Login

The rapid rise in the use of GLP-1 receptor agonists for weight management is reshaping conversations around nutrition, appetite, and exercise participation. While these medications can be effective for glycemic control and weight loss, their appetite-suppressing effects introduce new considerations for fueling and training consistency.

Emerging research indicates that individuals using GLP-1 medications may unintentionally reduce energy intake below levels needed to support regular exercise. Reduced appetite, early satiety, and gastrointestinal side effects can make it difficult to consume adequate calories and protein, particularly on training days. As a result, some clients report early fatigue, reduced training tolerance, or difficulty maintaining lean mass.

Recent studies also suggest that rapid weight loss associated with GLP-1 use may include loss of fat-free mass if resistance training and sufficient protein intake are not maintained. This has important implications for strength, metabolic health, and long-term function, particularly among older adults or previously sedentary individuals.

For fitness professionals, awareness rather than intervention is the key responsibility. Screening for medication use, observing changes in energy levels, and reinforcing the importance of fueling for participation fall within scope and can meaningfully support adherence. When appropriate, collaboration with healthcare providers or registered dietitians may help ensure nutrition strategies align with both medical and training goals.

As GLP-1 use becomes more common, professionals who understand its implications for exercise tolerance and recovery will be better positioned to support sustainable participation rather than short-term weight-focused outcomes.